» Articles » PMID: 37558995

Polymorphic Variants at NDUFC2, Encoding a Mitochondrial Complex I Subunit, Associate with Cardiac Hypertrophy in Human Hypertension

Abstract

Background: A dysfunction of NADH dehydrogenase, the mitochondrial Complex I (CI), associated with the development of left ventricular hypertrophy (LVH) in previous experimental studies. A deficiency of Ndufc2 (subunit of CI) impairs CI activity causing severe mitochondrial dysfunction. The T allele at NDUFC2/rs11237379 variant associates with reduced gene expression and impaired mitochondrial function. The present study tested the association of both NDUFC2/rs11237379 and NDUFC2/rs641836 variants with LVH in hypertensive patients. In vitro studies explored the impact of reduced Ndufc2 expression in isolated cardiomyocytes.

Methods: Two-hundred-forty-six subjects (147 male, 59.7%), with a mean age of 59 ± 15 years, were included for the genetic association analysis. Ndufc2 silencing was performed in both H9c2 and rat primary cardiomyocytes to explore the hypertrophy development and the underlying signaling pathway.

Results: The TT genotype at NDUFC2/rs11237379 associated with significantly reduced gene expression. Multivariate analysis revealed that patients carrying this genotype showed significant differences for septal thickness (p = 0.07), posterior wall thickness (p = 0.008), RWT (p = 0.021), LV mass/BSA (p = 0.03), compared to subjects carrying either CC or CT genotypes. Patients carrying the A allele at NDUFC2/rs641836 showed significant differences for septal thickness (p = 0.017), posterior wall thickness (p = 0.011), LV mass (p = 0.003), LV mass/BSA (p = 0.002) and LV mass/height(p = 0.010) after adjustment for covariates. In-vitro, the Ndufc2 deficiency-dependent mitochondrial dysfunction caused cardiomyocyte hypertrophy, pointing to SIRT3-AMPK-AKT-MnSOD as a major underlying signaling pathway.

Conclusions: We demonstrated for the first time a significant association of NDUFC2 variants with LVH in human hypertension and highlight a key role of Ndufc2 deficiency-dependent CI mitochondrial dysfunction on increased susceptibility to cardiac hypertrophy development.

Citing Articles

Mitochondrial complex-1 as a therapeutic target for cardiac diseases.

Rai N, Venugopal H, Rajesh R, Ancha P, Venkatesh S Mol Cell Biochem. 2024; 480(2):869-890.

PMID: 39033212 DOI: 10.1007/s11010-024-05074-1.


Hypertension and Heart Failure: From Pathophysiology to Treatment.

Gallo G, Savoia C Int J Mol Sci. 2024; 25(12).

PMID: 38928371 PMC: 11203528. DOI: 10.3390/ijms25126661.


Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities.

Gallo G, Rubattu S, Volpe M Int J Mol Sci. 2024; 25(5).

PMID: 38473911 PMC: 10932393. DOI: 10.3390/ijms25052667.


Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Biomedicines. 2023; 11(12).

PMID: 38137330 PMC: 10740779. DOI: 10.3390/biomedicines11123109.

References
1.
Meng C, Jin X, Xia L, Shen S, Wang X, Cai J . Alterations of mitochondrial enzymes contribute to cardiac hypertrophy before hypertension development in spontaneously hypertensive rats. J Proteome Res. 2009; 8(5):2463-75. DOI: 10.1021/pr801059u. View

2.
Zhang W, Kowal R, Rusnak F, Sikkink R, Olson E, Victor R . Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 1999; 84(6):722-8. DOI: 10.1161/01.res.84.6.722. View

3.
Tang Y, Mi C, Liu J, Gao F, Long J . Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat. Cardiovasc Pathol. 2014; 23(2):101-6. DOI: 10.1016/j.carpath.2013.11.002. View

4.
Pillai V, Sundaresan N, Jeevanandam V, Gupta M . Mitochondrial SIRT3 and heart disease. Cardiovasc Res. 2010; 88(2):250-6. PMC: 2952535. DOI: 10.1093/cvr/cvq250. View

5.
Forte M, Bianchi F, Cotugno M, Marchitti S, De Falco E, Raffa S . Pharmacological restoration of autophagy reduces hypertension-related stroke occurrence. Autophagy. 2019; 16(8):1468-1481. PMC: 7469607. DOI: 10.1080/15548627.2019.1687215. View